Dr Hannah Stevens is a consultant haematologist, and a research officer within the Atherothrombosis and Vascular Biology laboratory at the Baker Institute. Hannah earned her PhD through Monash University, where she specialised in approaches for the prediction of venous thromboembolism risk. Currently, Hannah is undertaking a research fellowship at the University of Cambridge. Her research in Cambridge focuses on using large datasets and multi-omic data to improve risk prediction methodologies for venous thrombosis and anticoagulant-related bleeding.

Dr. Godley received scientific training in the Marchesi (Yale), Wiley (Harvard), and Varmus (UCSF/NIH) laboratories and medical training at Northwestern. After training in Internal Medicine and Hematology-Oncology at The University of Chicago, she held a long-time faculty position at the University of Chicago and recently relocated to Northwestern University where she is the Jeffrey and Marianne Silver Family Professor of Oncology; Director of the Silver Family Blood Cancer Institute and Clinical Director of Cancer Genetics for the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology/Oncology. Dr. Godley also runs an independent research laboratory focused on understanding the molecular pathways that drive hematopoietic malignancies, especially how germline predisposition alleles contribute to individual and family risk. Dr. Godley has contributed to the recognition of germline DDX41, ETV6, and CSF3R variants as risk factors to developing hematopoietic malignancies. She is also studying how deleterious germline RUNX1, CHEK2, and BRCA1/2 variants drive these cancers, especially considering how the development of clonal hematopoiesis and inflammatory pathways contribute to tumorigenesis. Dr. Godley has shown that germline contribution to hematopoietic malignancies occurs throughout the entire age range of life and is more common than previously anticipated, which has important implications for the allogeneic hematopoietic stem cell donor pool. Along with David Wu (Univ of Washington), Dr. Godley co-chairs the Myeloid Malignancy Variant Curation Expert Panel, which has provided variant curation rules for RUNX1 that are now in use throughout the world and is currently developing similar rules for GATA2 and DDX41. Dr. Godley’s group also studies how covalently modified cytosines in DNA control cellular differentiation, specifically how hypoxia alters epigenetic modifications with hematopoietic stem and progenitor cells, especially during erythropoiesis. Dr. Godley practices bench to bedside medicine that advances patient care through a deep appreciation of the latest scientific findings.

Andy is a Consultant Haematologist working in a joint post between NHS Blood and Transplant and Newcastle Hospitals, UK. He is Secretary to the National Blood Transfusion Committee in England, Clinical Lead for the Patient Blood Management and Components clinical team, supports the NHSBT Red Cell Immuno-haematology clinical service and is Clinical Lead for Transfusion and Myeloma at Newcastle Hospitals. He supports regional and national transfusion education initiatives and is involved in guideline-writing and examining. He is an active PI, and UK CI for the REDDS-2 clinical trial.